文献速递肝病消化道肿瘤与早癌

直接抗病毒药物时代肝移植登记患者中新发肝细胞癌

De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
PubMed 文献 · Hepatology · 2018-01-01

研究基于肝移植受者科学登记数据库,纳入2003年1月至2015年12月因肝硬化列于肝移植等待名单的48158例患者,按登记日期分为3个时代,分析直接抗病毒药物时代新发肝细胞癌发生率。在20039例丙型肝炎患者中,时代3较时代1肝细胞癌发生率升高49%(IRR 1.49,95%CI 1.24-1.79),但竞争风险分析中时代与肝细胞癌不再相关(亚分布风险比0.83,95%CI 0.69-1.00)。

要点

  • 48158例等待肝移植的肝硬化患者中,3112例(6.5%)在中位493天后获得肝细胞癌例外。
  • 在20039例丙型肝炎患者中,时代3较时代1肝细胞癌发生率升高49%(IRR 1.49,95%CI 1.24-1.79)。
  • 竞争风险分析中时代与肝细胞癌不再相关(亚分布风险比0.83,95%CI 0.69-1.00)。

核心结论

  • 在这一大型基于人群的肝移植登记队列中,丙型肝炎患者肝细胞癌发生率在直接抗病毒药物时代有所增加;竞争风险分析提示这可能由该时期丙型肝炎人群肝移植率和等待名单死亡率的变化所解释。

研究设计与样本

  • 研究利用肝移植受者科学登记数据库,识别2003年1月至2015年12月因肝硬化列于肝移植等待名单的个体,排除列名时或180天内获得肝细胞癌例外者。
  • 患者按登记日期分为3个时代:时代1(2003-2010)、时代2(2011-2013)、时代3(2014-2015)。
  • 纳入48158例合格等待名单登记患者,其中20039例为丙型肝炎患者;采用Cox回归和竞争风险分析(以死亡和肝移植为竞争事件)评估肝细胞癌与登记时代的关联。

主要发现

  • 48158例合格等待名单登记患者中,3112例(6.5%)在中位493天后获得肝细胞癌例外。
  • 在20039例丙型肝炎患者中,时代3较时代1肝细胞癌发生率升高49%(IRR 1.49,95%CI 1.24-1.79)。
  • 多因素分析中,时代3较时代1肝细胞癌风险更高(风险比1.22,95%CI 1.01-1.48)。
  • 在多变量竞争风险分析中(以死亡和肝移植为竞争事件),时代与肝细胞癌不再相关(亚分布风险比0.83,95%CI 0.69-1.00)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) receiving direct acting antivirals (DAAs) has been debated. This study aims to describe the incidence of HCC among patients listed for liver transplantation (LT) in the DAA era. Individuals with cirrhosis listed for LT from January 2003 to December 2015 were identified using the Scientific Registry for Transplant Recipients database. Patients with HCC at listing or HCC exception within 180 days were excluded. Patients were divided into three eras based on listing date: eras 1 (2003-2010), 2 (2011-2013), and 3 (2014-2015). Incidence rates of HCC were calculated by era and compared using incident rate ratios (IRRs). The association between HCC and listing era was evaluated using Cox regression and competing risk analyses, the latter considering death and LT as competing events. Of the 48,158 eligible wait-list registrants, 3112 (6.5%) received HCC exceptions after a median of 493 days. In 20,039 individuals with HCV, the incidence of HCC was 49% higher in era 3 versus era 1 (IRR 1.49, 95% confidence interval [CI] 1.24-1.79). In multivariate analysis, those in era 3 had a higher hazard of HCC compared with era 1 (hazard ratio 1.22, 95% CI 1.01-1.48). However, in multivariable competing risks analysis, with death and LT considered as competing events for de novo HCC, era was no longer associated with HCC (subdistribution hazard ratio 0.83, 95% CI 0.69-1.00). CONCLUSION: In this large population-based cohort of LT registrants, the incidence of HCC among HCV patients has increased in the DAA era. Competing risks analysis suggests that this may be explained by changes in rates of LT and wait-list mortality in the HCV population during this time. (Hepatology 2018; 00:000-000).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kwong AJ, Kim WR, Flemming JA, et al. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. Hepatology. 2018. PMID: 29672886. doi:10.1002/hep.30045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。